ARCHIVES

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

This article is from The Cancer Letter archive.

Vol. 25 No. 01 | January 8, 1999

Download PDF Visit The Full Archive

Related Articles

Novel Treatment Modalities Tested Against Bladder Cancer

May 27, 2005

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?

April 21, 1995

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004

Peer Review Study Team Plans Hearing

December 12, 1975

DCE Advisors OK Concepts for Registry, Grants In Breast Cancer

June 25, 1993

FDA To Limit Radiation Doses from Medical Imaging

February 12, 2010